Palatin Technologies, Inc. (PTNT)

OTCMKTS · Delayed Price · Currency is USD
0.1424
+0.0022 (1.57%)
At close: Jul 10, 2025
184.80%
Market Cap 6.69M
Revenue (ttm) 350.00K
Net Income (ttm) -23.33M
Shares Out n/a
EPS (ttm) -1.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 60,290
Average Volume 203,118
Open 0.1402
Previous Close 0.1402
Day's Range 0.1375 - 0.1445
52-Week Range 0.0350 - 0.1663
Beta n/a
RSI 55.44
Earnings Date Sep 30, 2025

About Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide m... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1986
Employees 30
Stock Exchange OTCMKTS
Ticker Symbol PTNT
Full Company Profile

Financial Performance

In 2024, Palatin Technologies's revenue was $4.49 million, a decrease of -7.49% compared to the previous year's $4.85 million. Losses were -$29.74 million, 23.7% more than in 2023.

Financial Statements

News

Palatin Technologies, Inc. (PTN) Q3 2025 Earnings Call Transcript

Palatin Technologies, Inc. (PTN) Q3 2025 - Earnings Conference Call May 14, 2025 11:00 AM ET Company Participants Carl Spana - CEO and President Stephen Wills - CFO, COO, Treasurer and Secretary Confe...

2 months ago - Seeking Alpha

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

Significant Progress in Obesity and Ocular Programs Teleconference and Webcast to be held today - May 14, 2025, at 11:00 AM EST CRANBURY, N.J. , May 14, 2025 /PRNewswire/ -- Palatin Technologies, Inc....

2 months ago - PRNewsWire

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025

Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection PL9654 and PL9655 down-regulate inflammatory...

2 months ago - PRNewsWire

Palatin Technologies Announces Closing of Reduced Public Offering

Company Transitioned onto the OTC Pink CRANBURY, N.J. , May 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC PINK: PTNT) ("Palatin" or the "Company"), a biopharmaceutical company developing fir...

2 months ago - PRNewsWire

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

The Company Intends to Request a Review of the Delisting Determination CRANBURY, N.J. , May 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin" or the "Company"), a biopharmaceutical company...

2 months ago - PRNewsWire